Biosergen
Biosergen advances its candidate with strong Q1 results
In its Q1 report, Biosergen highlights the successful completion of the second patient cohort in the proof-of-concept study with BSG005,...
News roundup Wednesday, May 21
Biosergen strengthens the board with an expert in anti-infective drugs
Biosergen, a biotechnology company focused on the development of...
News roundup Monday, May 12
Alligator Bioscience
Biosergen takes aim at climate-driven fungal infections
Research shows that climate change is driving the rapid...
Biosergen's CEO on the latest progress
As fungal infections continue to be recognized...
Biosergen scales up for future success
News roundup Wednesday, March 5
AcuCort
Biosergen's CEO: "These findings open up new possibilities"
Biosergen's antifungal drug candidate, BSG005, continues to show strong...
News roundup Tuesday, February 4
Sedana Medical
News roundup Monday, December 23
NanoEcho
The news sweep Friday 6 December
Hansa Biopharma
Notes
Mentice consolidates operations to Denver
Bio-Works secures million-dollar order from global pharmaceutical company
OncoZenge receives investment proceeds from Yangtian Bio-Pharmaceutical
Xspray Pharma confirms bioequivalence for XS003
Evaxion converts debt of EUR 3,5 million
NEWSLETTER
NEWS
AI-designed proteins are created in seconds
The price of Leqembi needs to be lowered in Japan
Merck gears up in lung diseases with giant acquisition
Upcoming events!
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The market is taking Trump's tariff threat in stride
The EU's new life science strategy – a step in the right direction or just fluff?
